INCIDENCE AND MANAGEMENT OF CARDIAC AND PULMONARY ADVERSE EVENTS FOLLOWING SINGLE-AGENT CARFILZOMIB TREATMENT IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Richards, Tiffany [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY NURSING FORUM | 2014年 / 41卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
151
引用
收藏
页码：E144 / E145
页数：2
相关论文
共 50 条
  • [31] A phase II study (PX-171-003-A1) of single-agent carfilzomib in patients with advanced relapsed and refractory multiple myeloma (RRMM)
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Jakubowiak, A. J.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Kunkel, L.
    Wear, S. Sandra
    Wong, A.
    Orlowski, R. Z.
    Jagannath, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 7 - 7
  • [32] A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use
    Jonsson, F.
    Ou, Y.
    Claret, L.
    Siegel, D.
    Jagannath, S.
    Vij, R.
    Badros, A.
    Aggarwal, S.
    Bruno, R.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2015, 4 (12): : 711 - 719
  • [33] Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    A J Jakubowiak
    D S Siegel
    T Martin
    M Wang
    R Vij
    S Lonial
    S Trudel
    V Kukreti
    N Bahlis
    M Alsina
    A Chanan-Khan
    F Buadi
    F J Reu
    G Somlo
    J Zonder
    K Song
    A K Stewart
    E Stadtmauer
    B L Harrison
    A F Wong
    R Z Orlowski
    S Jagannath
    Leukemia, 2013, 27 : 2351 - 2356
  • [34] Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study
    Jakubowiak, A. J.
    Siegel, D. S.
    Martin, T.
    Wang, M.
    Vij, R.
    Lonial, S.
    Trudel, S.
    Kukreti, V.
    Bahlis, N.
    Alsina, M.
    Chanan-Khan, A.
    Buadi, F.
    Reu, F. J.
    Somlo, G.
    Zonder, J.
    Song, K.
    Stewart, A. K.
    Stadtmauer, E.
    Harrison, B. L.
    Wong, A. F.
    Orlowski, R. Z.
    Jagannath, S.
    LEUKEMIA, 2013, 27 (12) : 2351 - 2356
  • [35] Final analysis of MM-014: Single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Hussein, M. A.
    Richardson, P. G.
    Jagannath, S.
    Singhal, S.
    Bensinger, W.
    Knight, R.
    Zeldis, J. B.
    Yu, Z.
    Olesnyckyj, M.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [36] Efficacy of single-agent bortezomib versus thalidomide in patients with relapsed or refractory multiple myeloma: a systematic review
    Harrison, SJ
    Prince, M
    Adena, M
    Smith, DK
    Hertel, J
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 104 - 105
  • [37] Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma
    Gupta, Vikas A.
    Nooka, Ajay K.
    Lonial, Sagar
    Boise, Lawrence H.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2013, 3 : 41 - 51
  • [38] Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
    Zhou, Xiang
    Fluechter, Patricia
    Nickel, Katharina
    Meckel, Katharina
    Messerschmidt, Janin
    Boeckle, David
    Knorz, Sebastian
    Steinhardt, Maximilian Johannes
    Krummenast, Franziska
    Danhof, Sophia
    Einsele, Hermann
    Kortuem, K. Martin
    Rasche, Leo
    CANCERS, 2020, 12 (04)
  • [39] Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma
    Vij, Ravi
    Wang, Michael
    Jagannath, Sundar
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    Kavalerchik, Edward
    Huang, Mei
    Siegel, David S.
    BLOOD, 2013, 122 (21)
  • [40] SINGLE-AGENT LENALIDOMIDE FOR THE TREATMENT OF RELAPSED OR REFRACTORY AGGRESSIVE LYMPHOMA PATIENTS
    Puccini, B.
    Chitarrelli, I.
    Antognoli, G.
    Fabbri, A.
    Rigacci, L.
    Lenoci, M. P.
    Lauria, F.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 288 - 288
12345